On Nov. 18, 2014, Health Canada, which is the equivalent of the Food & Drug Administration (FDA) in the United States, issued a warning that the Alzheimer’s disease drug galantamine (Razadyne or Razadyne ER) has been associated with rare, but serious and potentially fatal skin reactions. These skin reactions may include:
• severe rash with blisters and peeling skin;
• red rash covered with small pus-filled bumps that can spread over the body, sometimes with fever; and
• rash that may blister spots that look like a target.
The most dangerous of these reactions is the blistering rash with peeling skin, which may indicate Stevens Johnson Syndrome (SJS), which is a medical emergency. It causes skin damage similar to that caused by severe burns and usually requires hospitalization. Thus far, the FDA has not recommended a similar warning be issued in the United States. Our firm has handled a number of cases involving Stevens Johnson Syndrome. If you have questions about this condition, contact Frank Woodson, a lawyer in our Mass Torts Section, at 800-898-2034 or by email Frank.Woodson@beasleyallen.com. Frank has handeled a number of Stevens Johnson Syndrome claims.
Source: Public Citizen
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.